Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Literature DB >> 22012016

Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Shawn R Lockhart¹, Carol B Bolden, Naureen Iqbal, Randall J Kuykendall.

Abstract

Flucytosine and itraconazole are the only antifungal agents for which the Clinical Laboratory and Standards Institute recommendations include MIC breakpoint readings at 48 h only. Here we show good essential and categorical agreement between the flucytosine MIC readings at 48 and 24 h for Candida species.

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 22012016 PMCID： PMC3232968 DOI： 10.1128/JCM.05479-11

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

28 in total

1. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors: A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal: J Clin Microbiol Date: 2004-02 Impact factor: 5.948

Review 2. The role of antifungal susceptibility testing in the therapy of candidiasis.

Authors: Duane R Hospenthal; Clinton K Murray; Michael G Rinaldi
Journal: Diagn Microbiol Infect Dis Date: 2004-03 Impact factor: 2.803

3. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.

Authors: John W Baddley; Mukesh Patel; Marga Jones; Gretchen Cloud; Anita C Smith; Stephen A Moser
Journal: Diagn Microbiol Infect Dis Date: 2004-10 Impact factor: 2.803

4. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.

Authors: Susan Hadley; José A Martinez; Laura McDermott; Barbara Rapino; David R Snydman
Journal: J Antimicrob Chemother Date: 2002-02 Impact factor: 5.790

Review 5. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

Authors: Michael A Pfaller; David Andes; Maiken C Arendrup; Daniel J Diekema; Ana Espinel-Ingroff; Barbara D Alexander; Steven D Brown; Vishnu Chaturvedi; Cynthia L Fowler; Mahmoud A Ghannoum; Elizabeth M Johnson; Cynthia C Knapp; Mary R Motyl; Luis Ostrosky-Zeichner; Thomas J Walsh
Journal: Diagn Microbiol Infect Dis Date: 2011-05-04 Impact factor: 2.803

6. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors: M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal: J Clin Microbiol Date: 2011-02-02 Impact factor: 5.948

7. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors: M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191

8. The epidemiology of sepsis in the United States from 1979 through 2000.

Authors: Greg S Martin; David M Mannino; Stephanie Eaton; Marc Moss
Journal: N Engl J Med Date: 2003-04-17 Impact factor: 91.245

9. Mechanisms of action of 5-fluorocytosine.

Authors: A R Waldorf; A Polak
Journal: Antimicrob Agents Chemother Date: 1983-01 Impact factor: 5.191

10. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors: Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal: Clin Infect Dis Date: 2004-07-15 Impact factor: 9.079

7 in total

Review 1. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors: M A Pfaller; D J Diekema
Journal: J Clin Microbiol Date: 2012-06-27 Impact factor: 5.948

2. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.

Authors: Shawn R Lockhart; Naureen Iqbal; Angela A Cleveland; Monica M Farley; Lee H Harrison; Carol B Bolden; Wendy Baughman; Betsy Stein; Rosemary Hollick; Benjamin J Park; Tom Chiller
Journal: J Clin Microbiol Date: 2012-08-08 Impact factor: 5.948

3. Antifungal Effects and Potential Mechanisms of Benserazide Hydrochloride Alone and in Combination with Fluconazole Against Candida albicans.

Authors: Xueqi Chen; Jiyong Wu; Lei Sun; Jing Nie; Shan Su; Shujuan Sun
Journal: Drug Des Devel Ther Date: 2021-11-16 Impact factor: 4.162

7. Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module.

Authors: Sebastian Wurster; Pappanaicken R Kumaresan; Nathaniel D Albert; Paul J Hauser; Russell E Lewis; Dimitrios P Kontoyiannis
Journal: mBio Date: 2019-05-28 Impact factor: 7.867